RESUMEN

The management of the superficial bladder tumor is commonly performed by transurethral resection (TUR) and a following chemotherapy or immunotherapy with exception of Tis. A lot of doubts and questions raise in the management of pT1G3 bladder tumor (BT) for the high grade of recurrencies and progressions. Our experience from 1984 to 1994 about 109 patients (pts) with pT1G3 BT undergone to radical cystectomy (47 pts) and TUR (62 pts) allows us to state that when Tis is present a radical cystectomy is mandatory, but the TUR option must be followed to frequent and accurate random biopsies in order to discovery foci of Tis. In the case of pT1G3 monofocal there is always a therapeutic disconcerting.

Asunto(s)

Carcinoma de Células Transicionales/terapia , Neoplasias de la Vejiga Urinaria/terapia , Administración Intravesical , Antibióticos Antineoplásicos/administración & dosificación , Vacuna BCG/administración & dosificación , Biopsia , Carcinoma de Células Transicionales/patología , Carcinoma de Células Transicionales/cirugía , Terapia Combinada , Cistectomía , Estudios de Seguimiento , Humanos , Inmunoterapia , Mitomicina/administración & dosificación , Factores de Tiempo , Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/cirugía